Compare

Profound Medical Corp. vs Vivos Therapeutics, Inc. vs Nephros Inc vs Sonoma Pharmaceuticals, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearProfound Medical Corp.
PROF
Vivos Therapeutics, Inc.
VVOS
Nephros Inc
NEPH
Sonoma Pharmaceuticals, Inc.
SNOA
Year ended2025-12-312025-12-312025-12-312026-03-31
Revenue$16.10M$17.44M$18.79M$19.53M
Revenue growth (YoY)+50.7%+16.0%+32.7%+36.7%
Gross margin70.8%60.4%61.9%38.0%
Operating margin-256.3%-114.1%6.1%-12.6%
Net margin-264.4%-121.4%6.4%-16.3%
Net income-$42.57M-$21.17M$1.19M-$3.17M
EPS (Diluted)$1.41-$2.07$0.11-$1.89
Operating cash flow-$38.21M-$15.26M$1.60M-$3.93M
Free cash flow-$38.38M-$17.60Mn/a-$4.12M
Cash & equivalents$59.72M$2.03M$5.40M$2.40M
Total assets$77.47M$25.15M$13.64M$13.96M
Total liabilities$11.04M$26.70M$3.44M$10.87M
Shareholders' equity$66.43M-$1.49M$10.20M$3.10M
Return on year-end equity-64.1%n/a11.7%-102.6%
Shares outstanding36.29M9.29M10.64M1.80M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearProfound Medical Corp.Vivos Therapeutics, Inc.Nephros IncSonoma Pharmaceuticals, Inc.
Latest$16.10M
Ended 2025-12-31
$17.44M
Ended 2025-12-31
$18.79M
Ended 2025-12-31
$19.53M
Ended 2026-03-31
1 year earlier$10.68M
Ended 2024-12-31
$15.03M
Ended 2024-12-31
$14.16M
Ended 2024-12-31
$14.29M
Ended 2025-03-31
2 years earlier$7.20M
Ended 2023-12-31
$13.80M
Ended 2023-12-31
$14.24M
Ended 2023-12-31
$12.73M
Ended 2024-03-31
3 years earliern/a$16.02M
Ended 2022-12-31
$9.97M
Ended 2022-12-31
$13.27M
Ended 2023-03-31
4 years earliern/a$16.89M
Ended 2021-12-31
$10.22M
Ended 2021-12-31
$12.63M
Ended 2022-03-31